Connect with us
U S researchers are conducting a clinical trial designed to help understand rare but potentially serious systemic allergic reactions to COVID 19 mRNA vaccines the U S National Institutes of Health NIH said The single site trial will enroll up to 100 people aged 16 to 69 years who had an allergic reaction to the first dose of the COVID 19 mRNA vaccine Study participants will receive a second dose of vaccine as inpatients under carefully controlled conditions at the NIH s Clinical Centre in Bethesda Maryland At admission and during the inpatient stay participants will have breathing tests and frequent blood draws which will be used to discern details of any allergic or other responses to the vaccine The enrollees will also complete mental health questionnaires prior to at the time of and in the months following vaccination according to the NIH People who experienced an allergic reaction after receiving a COVID 19 mRNA vaccine may be hesitant to complete their vaccine regimen This study will help us determine if individuals who experienced moderate systemic allergic reactions can safely receive a second dose of a COVID 19 mRNA vaccine said Anthony Fauci director of the U S National Institute of Allergy and Infectious Diseases Xinhua NAN
U.S. launches trial on allergic reactions to COVID-19 mRNA vaccines
Coronavirus11 months ago

U.S. launches trial on allergic reactions to COVID-19 mRNA vaccines

U.S. researchers are conducting a clinical trial designed to help understand rare but potentially serious systemic allergic reactions to COVID-19...

COVID-19

The Nigeria Centre for Disease Control NCDC says death recorded so far due to the coronavirus stands at 1 171 with 246 new cases in the country The NCDC made this known on its verified website on Friday The agency said that the infections brought the total number of cases in the country to 67 220 The News Agency of Nigeria reports that Nigeria had tested 756 237 persons since the first confirmed case was announced on Feb 27 NAN recalls that the country had since April suffered over 67 000 cases as total infections hit 67 220 and total recovery and discharge stood at 62 686 The agency however said that there were two confirmed deaths within the last 24 hours with 101 patients discharged from isolation centers across the country The NCDC said that the new infection were spread across nine states and the Federal Capital Territory It noted that Lagos led in the number of cases with 81 73 in FCT 39 in Plateau and 25 in Kaduna Among other states were Ogun with 13 infections Bauchi 5 Rivers 4 and Ekiti Taraba and Kano 2 each The public health agency said that till date 67 220 cases had been confirmed 62 686 discharged and 1 171 deaths recorded in 36 states and the Federal Capital Territory The NCDC said that a multi sectoral national emergency operations centre EOC was activated at Level 3 and had continued to coordinate the national response activities Edited By Chidinma Agu Ismail Abdulaziz NAN
Nigeria’s COVID-19 death hits 1171, with 246 new cases -NCDC
The Nigeria Centre for Disease Control NCDC says death recorded so far due to the coronavirus stands at 1 171 with 246 new cases in the country The NCDC made this known on its verified website on Friday The agency said that the infections brought the total number of cases in the country to 67 220 The News Agency of Nigeria reports that Nigeria had tested 756 237 persons since the first confirmed case was announced on Feb 27 NAN recalls that the country had since April suffered over 67 000 cases as total infections hit 67 220 and total recovery and discharge stood at 62 686 The agency however said that there were two confirmed deaths within the last 24 hours with 101 patients discharged from isolation centers across the country The NCDC said that the new infection were spread across nine states and the Federal Capital Territory It noted that Lagos led in the number of cases with 81 73 in FCT 39 in Plateau and 25 in Kaduna Among other states were Ogun with 13 infections Bauchi 5 Rivers 4 and Ekiti Taraba and Kano 2 each The public health agency said that till date 67 220 cases had been confirmed 62 686 discharged and 1 171 deaths recorded in 36 states and the Federal Capital Territory The NCDC said that a multi sectoral national emergency operations centre EOC was activated at Level 3 and had continued to coordinate the national response activities Edited By Chidinma Agu Ismail Abdulaziz NAN
Nigeria’s COVID-19 death hits 1171, with 246 new cases -NCDC
COVID-192 years ago

Nigeria’s COVID-19 death hits 1171, with 246 new cases -NCDC

The Cuban Centre for State Control of Medicines Equipment and Medical Devices approved the launch of clinical trials of two COVID 19 candidate vaccines developed by the Cuban Centre of Genetic Engineering and Biotechnology CIGB official said CIGB Director Eulogio Pimentel Vazquez said this on Friday The clinical trials of candidate vaccines Mambisa and Abdala have been approved After a thorough review of the presented dossier that included the evidence of the results of the pharmaceutical development and animal trials Dr Pimental wrote on Twitter According to the CIGB the Mambisa vaccine will be injected through the nose to examine the immune response at the mucous level The aim of the Abdala vaccine trial is to evaluate its safety in the first phase and its immune response capacity in the second phase Apart from Mambisa and Abdala vaccines Cuba is conducting clinical trials of two other domestic vaccines Earlier in August Cuban Finlay Institute started developing Soberana 01 vaccine with trials expected to be finished in January 2021 At the end of October the state control authority approved the first phase trials of the Soberana 02 vaccine against the coronavirus disease Edited By Fatima Sule Ekemini Ladejobi NAN
Cuba starts clinical trials of 2 new domestic vaccines against COVID-19 – Authority
The Cuban Centre for State Control of Medicines Equipment and Medical Devices approved the launch of clinical trials of two COVID 19 candidate vaccines developed by the Cuban Centre of Genetic Engineering and Biotechnology CIGB official said CIGB Director Eulogio Pimentel Vazquez said this on Friday The clinical trials of candidate vaccines Mambisa and Abdala have been approved After a thorough review of the presented dossier that included the evidence of the results of the pharmaceutical development and animal trials Dr Pimental wrote on Twitter According to the CIGB the Mambisa vaccine will be injected through the nose to examine the immune response at the mucous level The aim of the Abdala vaccine trial is to evaluate its safety in the first phase and its immune response capacity in the second phase Apart from Mambisa and Abdala vaccines Cuba is conducting clinical trials of two other domestic vaccines Earlier in August Cuban Finlay Institute started developing Soberana 01 vaccine with trials expected to be finished in January 2021 At the end of October the state control authority approved the first phase trials of the Soberana 02 vaccine against the coronavirus disease Edited By Fatima Sule Ekemini Ladejobi NAN
Cuba starts clinical trials of 2 new domestic vaccines against COVID-19 – Authority
COVID-192 years ago

Cuba starts clinical trials of 2 new domestic vaccines against COVID-19 – Authority

Latest News

naija news headlines today register bet9ja rariya labaran hausa website shortner facebook downloader